Prelude Capital Management’s Vigil Neuroscience VIGL Stock Holding History

Prelude Capital Management’s Portfolio VIGL Stock Details VIGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-118,568	Closed	-$943K	–	1401
2025 Q2	$943K	Buy	+118,568	New	+$532K	0.09%	276
2024 Q3	–	Sell	-10,867	Closed	-$43.5K	–	1565
2024 Q2	$43.5K	Sell	10,867 -9,510	-47%	-$32.5K	﹤0.01%	1153
2024 Q1	$69.5K	Buy	+20,377	New	+$63.6K	﹤0.01%	1233

Other funds holding VIGL

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Prelude Capital Management's VIGL Position: Q3 2025 in Review

Prelude Capital Management sold out of Vigil Neuroscience (VIGL) in Q3 2025, closing a stake of 118,568 shares — an estimated $943K sold.

Prelude Capital Management first reported a position in VIGL in Q1 2024 and held it in 3 quarters. The position peaked at $943K in Q2 2025. 2 funds tracked by Wall St. Rank hold VIGL as of Q3 2025.

Prelude Capital Management reported no remaining Vigil Neuroscience position as of Q3 2025 after selling out during the quarter.
Prelude Capital Management sold 118,568 Vigil Neuroscience shares in Q3 2025, an estimated $943K.
Prelude Capital Management first reported a position in Vigil Neuroscience in Q1 2024 and held it in 3 quarters.
Prelude Capital Management's Vigil Neuroscience position peaked at $943K in Q2 2025.
2 funds tracked by Wall St. Rank held Vigil Neuroscience as of Q3 2025.

Based on Prelude Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.